Oral Azacitidine Yields Similar PK to Subcutaneous Azacitidine in MDS/CMML
The overall response rate (ORR) in patients with MDS (n = 11) was 50.0%, including 5 who achieved complete response (CR) and 2 who achieved marrow complete response. Additionally, 4 patients achieved hematologic improvement (HI), including 3 erythroid, 2 neutrophil, and 3 platelet HIs. Eight patients with MDS achieved stable disease, 2 had progressive disease, and 1 was not evaluable.
No patients with CMML responded to treatment. Five had stable disease, none had progressive disease, and 1 was not evaluable. Of 2 patients with AML, 1 achieved CR, and 1 was not evaluable.
Thirteen patients were red blood cell (RBC) transfusion-dependent at baseline; of those, 30.8% achieved 8 or more weeks of RBC transfusion independence. Median overall survival (OS) had not been reached as of most recent follow-up.